Daymark Wealth Partners LLC Increases Stock Position in Johnson & Johnson (NYSE:JNJ)

Daymark Wealth Partners LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 310,032 shares of the company’s stock after buying an additional 9,279 shares during the period. Johnson & Johnson comprises approximately 1.5% of Daymark Wealth Partners LLC’s holdings, making the stock its 17th biggest holding. Daymark Wealth Partners LLC’s holdings in Johnson & Johnson were worth $44,837,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Advisory Alpha LLC boosted its stake in shares of Johnson & Johnson by 7.2% during the 4th quarter. Advisory Alpha LLC now owns 7,216 shares of the company’s stock valued at $1,044,000 after buying an additional 485 shares during the last quarter. Corepath Wealth Partners LLC raised its holdings in Johnson & Johnson by 3.7% in the fourth quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company’s stock valued at $287,000 after acquiring an additional 70 shares in the last quarter. Bourne Lent Asset Management Inc. boosted its stake in Johnson & Johnson by 1.4% during the 4th quarter. Bourne Lent Asset Management Inc. now owns 14,366 shares of the company’s stock valued at $2,078,000 after acquiring an additional 200 shares during the last quarter. XML Financial LLC grew its holdings in Johnson & Johnson by 0.6% during the 4th quarter. XML Financial LLC now owns 69,537 shares of the company’s stock worth $10,057,000 after acquiring an additional 420 shares in the last quarter. Finally, Genesis Private Wealth LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $308,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity

In other news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Trading Up 0.1 %

Shares of JNJ stock opened at $146.76 on Friday. The firm has a market capitalization of $353.34 billion, a PE ratio of 22.07, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The stock has a fifty day moving average of $147.99 and a two-hundred day moving average of $155.98.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22,438,500 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the company earned $2.29 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on JNJ. Barclays decreased their price target on Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating for the company in a research note on Tuesday. Morgan Stanley decreased their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday. Wolfe Research initiated coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective on the stock. Citigroup lowered their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Finally, Raymond James reduced their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $170.06.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.